The tiered reward structure only has to be at or above the specified price level on the 3, 6, 9, or 12 month observation date. It was previously mentioned that the pricing needed to be sustained over that time period. 

<p><i><strong>The tiered reward structure only has to be at or above the specified price level on the 3, 6, 9, or 12 month observation date. It was previously mentioned that the pricing needed to be sustained over that time period. </strong></i></p> <p><strong id="dateline">NEW YORK CITY, NY / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / July 2, 2026 / </strong>Emerging Growth Research today issued a flash report on OSR Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/OSRH">OSRH</a>), formerly OSR Holdings, reaffirming its Buy-Emerging rating and 12-month price target of $10.00.</p><p>The flash report highlights OSRH's newly announced Shareholder Loyalty Program, a novel plan to reward long-term shareholders with Contingent Value Rights ("CVR") rather than pursuing a reverse stock split. The Company's Board has approved the plan, which remains subject to legal counsel's opinion, with a record date targeted for July 31, 2026.</p><p><strong>Key Highlights from the Flash Report:</strong></p><p><strong>Shareholder Loyalty Program via Contingent Value Rights:</strong></p><p>OSRH plans to distribute one non-transferable CVR for every share held as of the expected record date, at no cost to shareholders. As the Company's share price reaches a series of defined milestones over the twelve months following the record date, shareholders who continuously hold their shares automatically receive additional shares of common stock.</p><p><strong>Tiered, Cumulative Reward Structure:</strong></p><p>Rewards are delivered in four tiers: at a share price &#8805;$2.00 at the 3 month observation date, a CVR delivers 0.5 additional shares; &#8805;$3.00 at the 6 month observation date delivers 1.0 shares; &#8805;$4.00 at the 9 month observation date delivers 1.5 shares; and &#8805;$5.00 at the 12 month observation date delivers 2.0 shares. A shareholder who remains invested through all four milestones over 12 months would theoretically receive five additional shares per original share, growing their position to six times its original size.</p><p><strong>An Alternative to a Reverse Split:</strong></p><p>Emerging Growth Research believes the CVR structure is likely the first time a company has used this mechanism to provide an asymmetric upside incentive for shareholders, and views it as preferable to a reverse stock split. Rather than reducing share count and liquidity in a manner that could give short sellers another opportunity to press the stock lower, the program is designed to reward loyal holders with additional shares while potentially improving trading liquidity and discouraging short selling.</p><p><strong>Building on the $815 Million BCM Europe Licensing Deal:</strong></p><p>The loyalty program builds on the strategic strength of OSRH's $815 million licensing agreement this year with BCM Europe for VXM01. Emerging Growth Research notes that continued execution on the BCM Europe relationship, growth in 4PL, integration of Woori IO's non-invasive glucose monitor into the global wearables market through Big Tech partnerships, and progress in drug candidate development represent substantial sources of potential price upside.</p><p><strong>Share Price Dynamics and Potential Floor:</strong></p><p>OSRH shares have experienced volatility over the past year. Emerging Growth Research believes a potential floor may now be forming in the stock if short sellers are brought to heel by the new loyalty program's design.</p><p><strong>For a copy of the full flash report, please visit:</strong></p><p><a rel="nofollow" href="https://pr.report/nbia">https://emerginggrowth.com/wp-content/uploads/2026/07/OSRH_Flash-Report_7.2.26.pdf</a><br/>or<br/><a rel="nofollow" href="https://pr.report/nbib">https://emerginggrowth.com/profile/osrh/</a> (on the right side of the page as you scroll down)</p><p><strong>About OSR Health, Inc.</strong></p><p>Founded in 2020 and headquartered in Bellevue, Washington and Gyeonggi-do, South Korea, OSR Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/OSRH">OSRH</a>), formerly OSR Holdings, is a global healthcare holding company with operations in Korea and Switzerland. The Company has four wholly owned subsidiaries developing oral immunotherapies for the treatment of cancer and biologics for age-related and other degenerative diseases, as well as a diabetes-focused medical device developer advancing non-invasive glucose monitoring technology. OSRH also distributes medical devices and systems and is expanding into 4th party logistics (4PL).</p><p><strong>About Emerging Growth Research</strong></p><p>Emerging Growth Research is an independent equity research firm providing institutional-quality analysis on emerging and growth-stage companies. The firm delivers ongoing coverage, including Flash Reports on material developments, designed to enhance transparency and broaden investor awareness for companies participating in the Emerging Growth Conference platform.</p><p><strong>Forward-Looking Statements</strong></p><p>This press release contains forward-looking statements concerning business operations and financial performance as well as plans, objectives, and expectations for OSR Health, Inc. that are subject to risks and uncertainties. These statements include, but are not limited to, expectations regarding the proposed Shareholder Loyalty Program and its record date, legal counsel's opinion, licensing agreements, regulatory pathways, product development, and capital formation. Actual results may differ materially due to a variety of risks, including the possibility that the CVR program is not implemented as currently contemplated or at all, that non-binding agreements do not result in definitive transactions, that licensing deal milestones may not be realized, regulatory challenges, potential dilution from future financing activities, and financing constraints.</p><a href="https://app.accessnewswire.com/imagelibrary/019e8288-330c-4e23-8259-ad70ec55496c/egr-logo-for-accesswire.png" rel="nofollow"><img src="https://app.accessnewswire.com/imagelibrary/019e8288-330c-4e23-8259-ad70ec55496c/1186012/egr-logo-for-accesswire.png" style="width:396px;text-align:center;margin:0.9em auto;"></a><div> </div><div> </div><div> </div><div> </div><div> </div><p><strong>Contact:</strong></p><p>Emerging Growth Research<br/><a rel="nofollow" href="mailto:Research@EmergingGrowth.com">Research@EmergingGrowth.com</a><br/><a rel="nofollow" href="https://pr.report/nbic">www.EmergingGrowth.com</a></p><p><strong>SOURCE: </strong>Emerging Growth Research</p><br/><br/>View the original <a href='https://www.accessnewswire.com/newsroom/en/biotechnology/correction-from-source-emerging-growth-research-issues-flash-report-on-osr-health-inc-1186012'>press release</a> on ACCESS Newswire<br/><br/>
      <img src="https://app.accessnewswire.com/img.ashx?id=1186012" width="0" height="0"/>

OSRH

CORRECTION FROM SOURCE: Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target

OSR Health Unveils CVR Loyalty Program Aiming for Long-Term Shareholder Upside

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>The tiered reward structure only has to be at or above the specified price level on the 3, 6, 9, or 12 month observation date. It was previously mentioned that the pricing needed to be sustained over that time period.</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Emerging Growth Research reaffirms OSR Health&#039;s Buy-Emerging rating with a $10 target, spotlighting a novel CVR-based loyalty program as an alternative to a reverse split. The plan awards one CVR per share at record date (July 31, 2026) and unlocks additional shares as price milestones are hit over 12 months, potentially reinforcing ownership and liquidity. The disclosure notes BCM Europe’s $815 million licensing deal and ongoing 4PL and glucose-monitoring initiatives as catalysts for upside.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>OSR Health unveils a CVR-based loyalty program, not a reverse split.</li><li>Milestones: 3, 6, 9, 12 months trigger additional shares.</li><li>BCM Europe licensing deal supports upside; progress on wearables and drug programs noted.</li><li>Flash report reiterates Buy-Emerging target of $10.00 and 12-month view.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>OSR Health, Inc. (OSRH)</strong>: Subject of the CVR loyalty program; potential upside from milestone-based share rewards.</li><li><strong>BCM Europe</strong>: Licensing partner for VXM01; adds external growth catalyst and validation.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category: Corporate Developments. The piece centers on a strategic program (CVR-based loyalty) and a significant licensing deal, both of which can materially affect OSRH&#039;s capital structure and growth trajectory.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Record date for CVR set for July 31, 2026; could spark near-term flow.</li><li>Milestone thresholds create potential dilution risk if milestones are reached.</li><li>BCM Europe licensing deal provides substantial upside and validation.</li><li>Loyalty-program structure may curb short-selling incentives and improve liquidity.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>OSR Health, Inc. (OSRH) targets a 12-month price of $10.00 with Buy-Emerging rating.</li><li>Record date for CVR: July 31, 2026; one non-transferable CVR per share.</li><li>Tiered rewards: 3m ≥$2.00, 6m ≥$3.00, 9m ≥$4.00, 12m ≥$5.00.</li><li>Additional shares: up to 2.0 extra shares at 12 months; total up to 6x original.</li><li>Licensing deal: BCM Europe for VXM01 valued at $815 million this year.</li><li>OSRH operates in Korea and Switzerland; four subsidiaries; non-invasive glucose monitoring.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Bullish OSRH over the next 6–12 months as CVR-triggered upside and BCM Europe licensing momentum converge.</p>
  </section>
</section>


<p><i><strong>The tiered reward structure only has to be at or above the specified price level on the 3, 6, 9, or 12 month observation date. It was previously mentioned that the pricing needed to be sustained over that time period. </strong></i></p> <p><strong id="dateline">NEW YORK CITY, NY / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / July 2, 2026 / </strong>Emerging Growth Research today issued a flash report on OSR Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/OSRH">OSRH</a>), formerly OSR Holdings, reaffirming its Buy-Emerging rating and 12-month price target of $10.00.</p><p>The flash report highlights OSRH's newly announced Shareholder Loyalty Program, a novel plan to reward long-term shareholders with Contingent Value Rights ("CVR") rather than pursuing a reverse stock split. The Company's Board has approved the plan, which remains subject to legal counsel's opinion, with a record date targeted for July 31, 2026.</p><p><strong>Key Highlights from the Flash Report:</strong></p><p><strong>Shareholder Loyalty Program via Contingent Value Rights:</strong></p><p>OSRH plans to distribute one non-transferable CVR for every share held as of the expected record date, at no cost to shareholders. As the Company's share price reaches a series of defined milestones over the twelve months following the record date, shareholders who continuously hold their shares automatically receive additional shares of common stock.</p><p><strong>Tiered, Cumulative Reward Structure:</strong></p><p>Rewards are delivered in four tiers: at a share price &#8805;$2.00 at the 3 month observation date, a CVR delivers 0.5 additional shares; &#8805;$3.00 at the 6 month observation date delivers 1.0 shares; &#8805;$4.00 at the 9 month observation date delivers 1.5 shares; and &#8805;$5.00 at the 12 month observation date delivers 2.0 shares. A shareholder who remains invested through all four milestones over 12 months would theoretically receive five additional shares per original share, growing their position to six times its original size.</p><p><strong>An Alternative to a Reverse Split:</strong></p><p>Emerging Growth Research believes the CVR structure is likely the first time a company has used this mechanism to provide an asymmetric upside incentive for shareholders, and views it as preferable to a reverse stock split. Rather than reducing share count and liquidity in a manner that could give short sellers another opportunity to press the stock lower, the program is designed to reward loyal holders with additional shares while potentially improving trading liquidity and discouraging short selling.</p><p><strong>Building on the $815 Million BCM Europe Licensing Deal:</strong></p><p>The loyalty program builds on the strategic strength of OSRH's $815 million licensing agreement this year with BCM Europe for VXM01. Emerging Growth Research notes that continued execution on the BCM Europe relationship, growth in 4PL, integration of Woori IO's non-invasive glucose monitor into the global wearables market through Big Tech partnerships, and progress in drug candidate development represent substantial sources of potential price upside.</p><p><strong>Share Price Dynamics and Potential Floor:</strong></p><p>OSRH shares have experienced volatility over the past year. Emerging Growth Research believes a potential floor may now be forming in the stock if short sellers are brought to heel by the new loyalty program's design.</p><p><strong>For a copy of the full flash report, please visit:</strong></p><p><a rel="nofollow" href="https://pr.report/nbia">https://emerginggrowth.com/wp-content/uploads/2026/07/OSRH_Flash-Report_7.2.26.pdf</a><br/>or<br/><a rel="nofollow" href="https://pr.report/nbib">https://emerginggrowth.com/profile/osrh/</a> (on the right side of the page as you scroll down)</p><p><strong>About OSR Health, Inc.</strong></p><p>Founded in 2020 and headquartered in Bellevue, Washington and Gyeonggi-do, South Korea, OSR Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/OSRH">OSRH</a>), formerly OSR Holdings, is a global healthcare holding company with operations in Korea and Switzerland. The Company has four wholly owned subsidiaries developing oral immunotherapies for the treatment of cancer and biologics for age-related and other degenerative diseases, as well as a diabetes-focused medical device developer advancing non-invasive glucose monitoring technology. OSRH also distributes medical devices and systems and is expanding into 4th party logistics (4PL).</p><p><strong>About Emerging Growth Research</strong></p><p>Emerging Growth Research is an independent equity research firm providing institutional-quality analysis on emerging and growth-stage companies. The firm delivers ongoing coverage, including Flash Reports on material developments, designed to enhance transparency and broaden investor awareness for companies participating in the Emerging Growth Conference platform.</p><p><strong>Forward-Looking Statements</strong></p><p>This press release contains forward-looking statements concerning business operations and financial performance as well as plans, objectives, and expectations for OSR Health, Inc. that are subject to risks and uncertainties. These statements include, but are not limited to, expectations regarding the proposed Shareholder Loyalty Program and its record date, legal counsel's opinion, licensing agreements, regulatory pathways, product development, and capital formation. Actual results may differ materially due to a variety of risks, including the possibility that the CVR program is not implemented as currently contemplated or at all, that non-binding agreements do not result in definitive transactions, that licensing deal milestones may not be realized, regulatory challenges, potential dilution from future financing activities, and financing constraints.</p><a href="https://app.accessnewswire.com/imagelibrary/019e8288-330c-4e23-8259-ad70ec55496c/egr-logo-for-accesswire.png" rel="nofollow"><img src="https://app.accessnewswire.com/imagelibrary/019e8288-330c-4e23-8259-ad70ec55496c/1186012/egr-logo-for-accesswire.png" style="width:396px;text-align:center;margin:0.9em auto;"></a><div> </div><div> </div><div> </div><div> </div><div> </div><p><strong>Contact:</strong></p><p>Emerging Growth Research<br/><a rel="nofollow" href="mailto:Research@EmergingGrowth.com">Research@EmergingGrowth.com</a><br/><a rel="nofollow" href="https://pr.report/nbic">www.EmergingGrowth.com</a></p><p><strong>SOURCE: </strong>Emerging Growth Research</p><br/><br/>View the original <a href='https://www.accessnewswire.com/newsroom/en/biotechnology/correction-from-source-emerging-growth-research-issues-flash-report-on-osr-health-inc-1186012'>press release</a> on ACCESS Newswire<br/><br/>
      <img src="https://app.accessnewswire.com/img.ashx?id=1186012" width="0" height="0"/>

Emerging Growth Research reaffirms OSR Health's Buy-Emerging rating with a $10 target, spotlighting a novel CVR-based loyalty program as an alternative to a reverse split. The plan awards one CVR per share at record date (July 31, 2026) and unlocks additional shares as price milestones are hit over 12 months, potentially reinforcing ownership and liquidity. The disclosure notes BCM Europe’s $815 million licensing deal and ongoing 4PL and glucose-monitoring initiatives as catalysts for upside.

CORRECTION FROM SOURCE: Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News